Health & Fitness
Wed, April 1, 2009Tue, March 31, 2009Mon, March 30, 2009Fri, March 27, 2009Thu, March 26, 2009Wed, March 25, 2009Tue, March 24, 2009Mon, March 23, 2009Fri, March 20, 2009Thu, March 19, 2009Wed, March 18, 2009Tue, March 17, 2009Mon, March 16, 2009Sun, March 15, 2009Fri, March 13, 2009Thu, March 12, 2009Wed, March 11, 2009Tue, March 10, 2009Mon, March 9, 2009Fri, March 6, 2009Thu, March 5, 2009Wed, March 4, 2009Tue, March 3, 2009Mon, March 2, 2009Fri, February 27, 2009Thu, February 26, 2009Wed, February 25, 2009Tue, February 24, 2009Mon, February 23, 2009Sun, February 22, 2009Fri, February 20, 2009Thu, February 19, 2009Allos Therapeutics to Report 2008 Results on March 3, 2009
Published in Health and Fitness on Thursday, February 26th 2009 at 13:10 GMT, Last Modified on 2009-02-26 13:11:14 by Market Wire
WESTMINSTER, Colo.--([ BUSINESS WIRE ])--Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that Paul L. Berns, President and Chief Executive Officer, and members of Allos' senior management team will provide a company update and review 2008 results via webcast and conference call on Tuesday, March 3, 2009, at 4:15 p.m. ET.
The webcast of this call will be available from the homepage and the investors/media section of the Company's web site, [ www.allos.com ]. Alternatively, callers may participate in the conference call by dialing 800-762-8795 (domestic) or 480-248-5085 (international). Participants should reference the Allos Therapeutics conference call. Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through Friday, March 13, 2009. To access the replay, callers should dial 800-406-7325 (domestic) or 303-590-3030 (international) and use passcode 3992548#.
About Allos Therapeutics, Inc.
Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer. In February 2009, the Company announced the final results from PROPEL, the Company's pivotal Phase 2 trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The PROPEL trial was conducted under an agreement reached with the U.S. Food and Drug Administration under its special protocol assessment (SPA) process. Based on the results of the PROPEL trial, the Company intends to submit a New Drug Application to the U.S. Food and Drug Administration for pralatrexate for the treatment of relapsed or refractory PTCL in the first half of 2009. The Company is also investigating pralatrexate in patients with non-small cell lung cancer, bladder cancer and a range of lymphoma sub-types. The Company currently retains exclusive worldwide rights to pralatrexate for all indications. For additional information, please visit the Company's website at [ www.allos.com ].
Safe Harbor Statement
The 2008 results press release and conference call will contain forward-looking statements that involve significant risks and uncertainties, including those contained in the "Risk Factors" section of the company's Form 10-Q for the quarter ended September 30, 2008 and in the company's other periodic reports and filings with the Securities and Exchange Commission. Allos is providing the information contained in the press release and conference call as of the date of the release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise. The Company cautions investors not to place undue reliance on the forward-looking statements contained in the press release or the conference call. No forward-looking statement can be guaranteed and actual events and results may differ materially from those projected.
